ERCC-1、survivin表达与含顺铂方案一线化疗治疗晚期肺腺癌患者疗效和预后关系

Relationship between Expression of ERCC-1,survivin and both Efficiency and Prognosis of Cisplatin -contained First-line Chemotherapy in Advanced Lung Adenocarcinoma

目的分析晚期肺腺癌患者组织中错配切除修复蛋白（excisition repair cross complement-1，ERCC-1）、凋亡抑制蛋白survivin表达同含顺铂方案一线化疗疗效和生存时间之间的关系。方法收集1999年1月-2005年12月在本院接受含顺铂方案一线化疗的、病理确诊为晚期肺腺癌患者的腊块80例。采用免疫组化方法检测ERCC-1、survivin的表达，并同化疗疗效和生存时间进行比较。结果共有77例可以评价染色，ERCC-1阳性率为33．77％，survivin阳性率为53．25％。ERCC-1阳性表达患者一线化疗有效率低，并且TTP和PFS较短，survivin阳性表达患者生存较差。结论ERCC-1阳性同晚期肺腺癌含顺铂方案一线化疗耐药和预后不良相关，survivin阳性表达提示晚期肺腺癌预后不良。

Objective To analyze the relationship between expression of ERCC-1 （excisition repair cross complement-l）.survivin and sensitivity and prognosis of cisplatin contained regimens first-line chemotherapy in advanced lung adenocarcinoma. Methods IHC was used to evaluate expression of ERCC-1 and survivin in 80 pathologically confirmed advanced lung adenocarcinoma patients given cisplatin-contained regimens first-line chemotherapy. The response rate and survival time were analyzed according to the expression of ERCC-1 and survivin. Results Only 77 patients could be reviewed by IHC staining. The expression rates of ERCC-1 and survivin were 33. 77% and 53. 25% respectively. The worse response rate and shorter TTP/PFS could be identified in ERCC-1 positive group. Patients with positive expression of survivin had worse survival time. Conclusion Expression of ERCC-1 may be a molecular marker of cisplatin-conrained regimens first-line chemotherapy resistance and poor prognosis in advanced lung adenocarcinoma patients.Simiary expression of survivin predicates poor prognosis for patients with advanced lung adenocarcinoma.